Dean Capital Management Buys 36,162 Shares of Perrigo Company plc $PRGO

Key Points

• Dean Capital Management significantly increased its holdings in Perrigo Company plc by 219.1%, owning a total of 52,664 shares worth approximately $1.48 million after acquiring 36,162 additional shares.
• Perrigo's quarterly earnings report revealed an EPS of $0.57, missing expectations of $0.59, with a revenue of $1.06 billion, below the projected $1.08 billion.
• The company declared a quarterly dividend of $0.29, with a yield of 5.2%, and reported a negative dividend payout ratio of -200.00%.

Dean Capital Management grew its position in Perrigo Company plc (NYSE:PRGO - Free Report) by 219.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,664 shares of the company's stock after purchasing an additional 36,162 shares during the period. Dean Capital Management's holdings in Perrigo were worth $1,477,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Picton Mahoney Asset Management bought a new stake in shares of Perrigo during the 1st quarter worth about $42,000. Parallel Advisors LLC boosted its stake in shares of Perrigo by 176.9% during the 1st quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock worth $48,000 after acquiring an additional 1,095 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Perrigo by 138.3% during the 1st quarter. First Horizon Advisors Inc. now owns 1,754 shares of the company's stock worth $49,000 after acquiring an additional 1,018 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Perrigo by 62.0% during the 1st quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock worth $62,000 after acquiring an additional 849 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Perrigo by 110.4% during the 1st quarter. Blue Trust Inc. now owns 2,619 shares of the company's stock worth $73,000 after acquiring an additional 1,374 shares in the last quarter. Institutional investors own 95.91% of the company's stock.

Perrigo Stock Performance

NYSE:PRGO traded down $0.29 during mid-day trading on Friday, hitting $22.26. 1,328,437 shares of the company's stock traded hands, compared to its average volume of 1,424,538. The firm has a 50 day moving average of $25.00 and a two-hundred day moving average of $26.07. Perrigo Company plc has a 12 month low of $21.03 and a 12 month high of $30.93. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -38.38 and a beta of 0.48. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81.

Perrigo (NYSE:PRGO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.59 by ($0.02). Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the company earned $0.53 EPS. Perrigo's revenue for the quarter was down .9% compared to the same quarter last year. On average, equities analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Friday, August 29th will be given a $0.29 dividend. The ex-dividend date is Friday, August 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 5.2%. Perrigo's dividend payout ratio (DPR) is currently -200.00%.

Insider Transactions at Perrigo

In other news, Director Geoffrey M. Parker acquired 4,375 shares of Perrigo stock in a transaction on Monday, August 18th. The stock was bought at an average price of $22.97 per share, for a total transaction of $100,493.75. Following the transaction, the director owned 33,287 shares of the company's stock, valued at $764,602.39. The trade was a 15.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Eduardo Guarita Bezerra acquired 3,000 shares of Perrigo stock in a transaction on Monday, August 18th. The stock was purchased at an average price of $22.74 per share, with a total value of $68,220.00. Following the transaction, the chief financial officer directly owned 48,949 shares in the company, valued at approximately $1,113,100.26. This trade represents a 6.53% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 10,118 shares of company stock worth $232,699 over the last 90 days. Insiders own 0.40% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price target on Perrigo from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded Perrigo from a "hold" rating to a "buy" rating in a research note on Friday, September 5th. Finally, JPMorgan Chase & Co. decreased their target price on Perrigo from $38.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $33.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.